Bayard D Clarkson

Title: Bayard D Clarkson: Innovator in Cancer Research

Introduction

Bayard D Clarkson is a notable inventor based in New York, NY (US). He has made significant contributions to the field of cancer research, particularly in understanding chronic myelogenous leukemia (CML). His work has implications for the development of targeted therapies for this type of cancer.

Latest Patents

Clarkson holds a patent related to a human gene/protein involved in chronic myelogenous leukemia. The patent describes the chimeric p120^bcr-abl protein, which exhibits elevated protein tyrosine kinase activity compared to the normal c-abl tyrosine kinase. The presence of this protein is characteristic of CML. His research identified a novel protein, p62^dok, which is associated with the p120 ras GTPase-activating protein (GAP) and is rapidly tyrosine phosphorylated upon activation of the c-kit receptor. This discovery implicates p62^dok as a key component in the signal transduction pathway downstream of receptor tyrosine kinases.

Career Highlights

Throughout his career, Clarkson has worked with prestigious institutions such as Cold Spring Harbor Laboratory and the Sloan-Kettering Institute for Cancer Research. His research has contributed to a deeper understanding of the molecular mechanisms underlying CML, paving the way for potential therapeutic advancements.

Collaborations

Clarkson has collaborated with notable colleagues, including Nicholas A Carpino and Ryuji Kobayashi. Their combined expertise has furthered research in the field of cancer biology.

Conclusion

Bayard D Clarkson's innovative work in cancer research, particularly regarding chronic myelogenous leukemia, highlights his role as a significant inventor in the scientific community. His contributions continue to influence the understanding and treatment of this challenging disease.